Refereed Journal Articles:

  1. Steele M and Narendran A. Mechanisms of Defective Erythropoiesis and Anemia in Pediatric Acute Lymphoblastic Leukemia (ALL). Ann Hematol. 2012 Apr 29. [Epub ahead of print].
  2. de Oliveira C, Brassesco MS, Scrideli CA, Tone LG and Narendran A. MicroRNA Expression and Activity in Pediatric Acute Lymphoblastic Leukemia (ALL). Pediatric Blood and Cancer. 2012 Apr 10. doi: 10.1002/pbc.24167. [Epub ahead of print].
  3. Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE. Polo-Like Kinase 1 (PLK1) Inhibition Kills Glioblastoma Multiforme Brain Tumour Cells in Part Through Loss of SOX2 and Delays Tumour Progression in Mice. Stem Cells. 2012. 30(6):1064-75
  4. Mineyko A, Narendran A, Fritzler M, B. Comm, Wei, X-C, Schmeling H and Kirton A. Inflammatory biomarkers of pediatric focal cerebral arteriopathy. In press. Neurology. 2012.
  5. Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell Int. 2011. 29;11(1):44-55.
  6. Banderali U, Belke D, Singh A, Jayanthan A, Giles WR, Narendran A. Curcumin Blocks Kv11.1 (erg) Potassium Current and Slows Proliferation in the Infant Acute Monocytic Leukemia Cell line THP-1. Cell Physiol Biochem. 2011. 28(6):1169-80.
  7. Maddigan A, Truitt L, Arsenault R, Freywald T, Allonby O, Dean J, Narendran A, Xiang J, Weng A, Napper S, Freywald A. EphB Receptors Trigger Akt Activation and Suppress Fas Receptor-Induced Apoptosis in Malignant T Lymphocytes. J Immunol. 2011. 1;187(11):5983-94.
  8. Baderali U, Jayanthan A, Hoeksma K, Narendran A, Giles, W. Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents. J Neurooncol. 2011. 107(1):111-9.
  9. Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A. Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Onco Targets Ther. 2011. 4:149-68.
  10. Mummery A, Narendran A, Lee KY. Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia. Curr Cancer Drug Targets. 2011. 11(7):882-93.
  11. Singh A, Jayanthan A, Farran A, Elwi AN, Kim SW, Farran P, Narendran A. Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition. Leuk Res. 2011. 35(12):1649-57.
  12. Jayanthan A, Incoronato A, Blackmore C, Bernoux D, Lewis VA, Stam R, Whitlock JA and A. Narendran, Cytotoxicity, Drug Combinability, and Biological Correlates of ABT-737 Against Acute Lymphoblastic Leukemia Cells with MLL Rearrangement. Pediatr Blood Cancer. 2011 Mar;56(3):353-60.
  13. Koro K, Parkin, S, Yang, A, Narendran A, Egan C and A. Magliocco. Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for Osteopontin in affecting breast cancer cell migration. Breast Cancer Research and Treatment. 2011 Feb;126(1):73-83.
  14. Blackmore C, Jayanthan A, Ujack E, Magliocco A, Narendran A. Analysis of multiple growth regulatory proteins using dissociable staining antibody arrays on solid tumor biopsy specimens. Fetal and Pediatric Pathology. Fetal Pediatr Pathol. 2011 Feb;30(3):177-88.
  15. Miettunen, P. Narendran, A. Jayanthan, A, Behrens and E Cron, R Successful treatment of severe pediatric rheumatic disease associated macrophage activation syndrome with IL-1 inhibition following conventional immunosuppressive therapy. Rheumatology (Oxford). 2011 Feb;50(2):417-9.
  16. Sooriyaarachchi M, Narendran A and Gailer J. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro. Royal Society of Chemistry Journal, Metallomics. 2011 Jan;3(1):49-55.
  17. Blackmore C, Coppes MJ and Narendran A. A Review of Candidate Genes and Potential Targets for Therapeutics in Wilms tumor. Clin Transl Oncol. 2010 Sep;12(9):597-605.
  18. Ho, J. Leung, A. Narendran, A. Obesity as a Complication of Cancer in Children. In Overweightness and Walking. Editors: Caleb I. Black. Nova Scientific Publishers. NY . Sept. 2010.
  19. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphoblastic leukemia (ALL): Review from an international consensus conference. Pediatric Blood and Cancer. Jul 1;54(7):872-8., 2010.
  20. Jayanthan A, Mittunen P, Incoronato A, Ortiz C, Anderson R, Lewis VA and A Narendran. Childhood Acute Lymphoblastic Leukemia (ALL) in Children Presenting with Severe Osteolysis: A model to study leukemia –bone interactions and potential targeted therapeutics. Pediatric Hematology Oncology. 2010 Apr;27(3):212-27.
  21. Jayanthan, A, Trippett, T, Howard, Horton, T, Lewis, V. and A. Narendran. Targeting BCL-2 family of proteins in Hodgkin's Lymphoma: In vitro cytotoxicity, target modulation and drug combination studies of the BCL-2 homology mimetic ABT-737. Leuk Lymphoma. 2009 July;50(7):1174-82.
  22. Narendran, A. Leung, A. Ho, J. Influence and Implications of Nutrition and Metabolic Factors on the Growth and Survival of Pediatric Cancer Cells: The IGF Connection. In Obesity and Cancer Research. Editors: Pauline R. Ramonde and Eva H. Fochas. Nova Scientific Publishers. NY. Aprl 2009.
  23. Jayanthan, A. Fowler, J. Hawkins, L. Lamers, F. Teja, B. Incoronato, A. Anderson, R and Narendran. A. Effects of Hsp90 inhibition in neuroblastoma: Analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. Journal of novel therapeutics and Oncology; 7(3):183-93. 2008.
  24. Narendran A, Coppes L, Jayanthan A, Coppes M, Teja B, Bernoux D, George D, Strother D. J. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeuticss. Neurooncol. Nov; 90(2):171-80. 2008.
  25. Jiang, G. Freywald, T. Webster, J. Kozan, D. Geyer, R. DeCoteau, J. Narendran, A and Freywald, A. In human leukemia cells ephrin-B-induced invasive activity is supported by Lck and is associated with reassembling of lipid raft signaling complexes. Molecular Cancer Research.2008 Feb;6(2):291-305. 2007.
  26. Bagatell R, Gore L, Egroin M, Heller G, Boucher N, Zuhowski E, Whitlock J, Hunger S, Narendran A, Katzenstein R, Arceci R, Bolken J, Herzog C, Whitesell S, Ivy P and T. Trippett. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study. Clin Cancer Res. 2007 Mar 15;13(6):1783-8.
  27. Connor AM, Berger S, Narendran A, Keystone EC. Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts. Arthritis Res Ther. 2006 Jun 14;8(4):R94 [Epub ahead of print]
  28. Ganjavi H, Gee M, Narendran A, Parkinson N, Krishnamoorthy M, Freedman MH, Malkin D. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther. 2006 Apr;13(4):415-9.
  29. Hawkins, L., Jayanthan A., and Narendran, A. Effects of 17-Allylamino-17-demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with respect to Bcr-Abl status and Imatinib Mesylate Sensitivity. Pediatr Res. 2005 Mar;57(3):430-7.
  30. Barlow JW, Wiley JC, Mous M, Narendran A, Gee M, Goldberg M, Sexsmith E, Malkin D. Differentiation of Rhabdomyosarcoma Cell lines Using Retinoic Acid. Pediatric Blood and Cancer. Pediatr Blood Cancer. 2006 Nov;47(6):773-84.
  31. Hawkins, L. and Narendran A. The Geldanamycin derivative 17-AAG decreases VEGF secretion and leukemia growth support by Trisomy 8 bone marrow stromal cells from Myelodysplastic syndrome (MDS). Pediatric Hematology and Oncology 22:1-11, 2005.
  32. Ganjavi H, Gee M, Narendran A, Freedman MH, Malkin D. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther. 2005 Apr;12(4):397-406.
  33. Narendran, A. and M.H.Freedman. Characterization of Bone Marrow Stromal Abnormalities in a Patient with Constitutional Trisomy 8 Mosaicism and Myelodysplastic Syndrome. Pediatric Hematology and Oncology, 21(3). 2004.
  34. Dror, Y, Grunegbaum, E, Hitzler, H., Narendran, A., Freedman, M.H., and C. Roifman. Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology. Pediatr Res. 2004 Mar;55(3):472-7.
  35. Narendran A, Ganjavi H, Morson M, Conner A, Keystone E, Malkin D, Freedman MH. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Experimental Hematology,(8):693-701 2003.
  36. Narendran,A., Monteleone,P., Steele,D. and J.Kelleher. Successful treatment of disseminated relapsed medulloblastoma in an infant by primary radiotherapy. J. Pediatric Oncol. 2001, 23: 51.
  37. Rahemtulla, A., Kundig, T.M., Narendran, A., Bachmann, M.F., Julius M., Paige, C.J., Ohashi, P.S., Zinkernagel, R.M. and T.W. Mak. Class II MHC complex-restricted T cell function in CD4-deficient mice. Eur. J. Immunol. 1994,24:2213.
  38. Mader, R., Narendran, A., Lewtas.J, Bykerk, V., Goodman, R.C., Dickson, J.R., and E.C.Keystone. Systemic vasculitis following influenza vaccination-report of 3 cases and literature review. J. Rheumatology. 1993, 20(8):1429.
  39. Matsuyama, T., Kimura, T., Kitagawa, M., Ohashi, P., Suzuki, H., Kishihara, K., Wakeham, A., Watanabe, N., Kawakami, T., Furlonger, C., Narendran, A., Frigerio, E., Banerjee, B., Paige, C.J., Tanaguchi, T. and T.W. Mak.Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993, 75:83.
  40. Narendran, A., Ramsden, D., Cumano, A., Wu, G. and Paige, C.J. B cell developmental defects in X linked immunodeficiency. International Immunology 1993, 5:139.
  41. Molina, T.J., Kishihara, K., Siderovski, D.P., Davidson, D., Narendran, A., Timms, E., Wakeham, A., Paige, C.J., Hartmann, K., Van Eejik, W., Veillette, A. and T.W. Mak. Profound block in early thymocyte development in mice lacking p56lck. Nature 1992, 357:161.
  42. Cumano, A., Narendran, A. and Paige, C.J. Factors produced by stromal cells involved in B cell development. Adv. Exp Med Biol. 1992. 303:191.
  43. Narendran, A., Cumano, A. and Paige, CJ. The stromal cell line S17 supports the growth of LPS stimulated CBA/N B cell colonies in vitro. European J. Immunol. 1992. 22:1001.
  44. Rahemtulla A, Fung-Leung WP, Schilham MW, Kundig TM, Sambhara SR, Narendran A, Arabian A, Wakeham A, Paige CJ, Zinkernagel RM, et al. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature. 1991, 353:180.
  45. Keystone, E.C., Poplonski, L., Snow, K.M., Shore, A., Narendran, A. and Harth, M. Reconstitution of impaired autologous mixed lymphocyte reactivity in rheumatoid arthritis. Autoimmunity, 1990, 8:199.
  46. Narendran, A. and Hoffman, S.A. Characterization of the brain reactive autoantibodies in murine models of SLE. J. Neuroimmunology, 1989, 24:113.
  47. Narendran, A. and Hoffman, S.A. Identification of autoantibody reactive integral brain membrane antigens - A two dimensional analysis. J. Immunol. Methods 1988, 114:227.
  48. Narendran, A. and Hoffman S.A. Autoantibody reactive integral membrane antigens of thymocytes and brain. Advances in Neuroimmunology, 1988, 540:466.
  49. Hoffman, S.A., Narendran, A., Shucard, D.W. and Harbeck, R.J. Auto antibodies, immune complexes and behavioral disorders: Neuropsychiatric involvement in systemic lupus erythematosus. Current Trends Review, Drug development Research, 1988, 15:237.
  50. Hough, D., Narendran, A. and Hall, N.D. Heterogeneity of Fc Receptor expression on human cell lines. Immunology letters, 1983, 7:85.